Research programme: liver metastases gene therapy - Custos Biotechnologie GmbH
Alternative Names: Custos 1; Custos 2Latest Information Update: 27 Apr 2007
At a glance
- Originator Custos Biotechnologie
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer metastases
Most Recent Events
- 27 Apr 2007 Discontinued - Preclinical for Cancer metastases in Germany (unspecified route)
- 12 Aug 2003 Preclinical trials in Cancer metastases in Germany (unspecified route)